Explore more price target data and ratings for Castle Biosciences, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Castle Biosciences, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. T…
Q2 2026 revenue grew 20% year-over-year to $103.5 million, with strong volume growth in TissueCypher and DecisionDx-Melanoma. 2026 revenue guidance was raised to $365–$375 million, and positive adjusted EBITDA is expected for the remainder of 2026.Based on Castle Biosciences, Inc. [CSTL] Q2 2026 Au…
Q2 2026 saw 20% revenue growth to $103.5M, driven by strong test volume increases, especially for TissueCypher and DecisionDx-Melanoma. Guidance for 2026 revenue was raised to $365–$375M, with positive adjusted EBITDA expected for the remainder of 2026.Based on Castle Biosciences, Inc. [CSTL] Q2 20…
Q2 2026 saw 32% year-over-year growth in core test volumes and revenue guidance raised to $365–375M. Adjusted gross margin was 76.3% and adjusted EBITDA reached $12.4M, with strong cash reserves and continued clinical adoption across segments.Original document: Castle Biosciences, Inc. [CSTL] Slide…
Castle Biosciences reported results for 2026 with revenue of $103.55M, up from $86.19M a year earlier, while net loss was ($2.06M) versus net income of $4.52M in the prior year and diluted EPS was ($0.07) compared with $0.15— according to the company's 10-Q filing.Financial Highlights¹ Reported as…
